INTRODUCTION
Severe malnutrition has been associated with adverse outcomes among patients with cirrhosis and following liver transplantation. [1] [2] [3] The prevalence of malnutrition in cirrhosis is reported to be 50% to 90%, and the nutritional status predicts morbidity and mortality in this patient population. Multiple factors contribute to malnutrition, including increased resting energy expenditure and hypermetabolism, fat maldigestion and malabsorption, altered macronutrient metabolism, anorexia and micronutrient deficiencies. Fat malabsorption, use of diuretics, and anorexia contribute to micronutrient deficiencies. 4 Vitamin and mineral deficiencies are common in cirrhosis regardless of the etiology. Previous studies investigated the effect of vitamin D, vitamin A, and zinc deficiencies individually in patients with cirrhosis. [5] [6] [7] [8] [9] [10] Vitamin D deficiency was associated with hepatic decompensation and higher mortality rates. 6, 8, 10 Vitamin A deficiency was frequent in patients with cirrhosis and may also have predicted a more severe disease course. 11 Zinc deficiency correlated with survival and the severity of disease. 9 Although these micronutrients have been studied individually in cirrhosis, to our knowledge there has not been a comprehensive review of these deficiencies to date. Furthermore, specific recommendations regarding the clinical assessment and treatment of these deficiencies in cirrhosis are poorly standardized. The current guidelines from the American Association for the Study of Liver Diseases (AASLD) regarding liver transplantation evaluation recommend measuring vitamin D with no further recommendations on measurment of vitamin A and zinc levels. 12 In this narrative review, we disucss the mechanisms of vitamin D, vitamin A, and zinc deficiencies in cirrhosis and the clinical assessment of affected patients, their outcomes based on the current literature, and appropriate further management.
VITAMIN D DEFICIENCY IN CIRRHOSIS
Vitamin D deficiency occurrs in up to 1 billion people worldwide and approximately 25% to 50% of the adult population in the United States. 13, 14 Vitamin D is an important secosteroid most widely known for its role in calcium homeostasis and bone mineralization, but has gained recognition for its extraskeletal effects, including the pathophysiology and treatment of chronic diseases, the immune system, and cellular proliferation and differentiation. [15] [16] [17] First reported in patients with cirrhosis in the 1970s, inadequate levels of vitamin D are common in cirrhosis, occurring in up to 93% of patients, with severe vitamin D deficiency being present in as many as one-third of patients. 15 Epidemiologic, clinical, and diagnostic information regarding deficiency of vitamin D are listed in table 1. 8, 10, 15, [18] [19] [20] [21] [22] [23] Vitamin D deficiency occurs in cirrhosis of all etiologies, and is not limited to patients with cholestatic liver disease (Table 2) . 5, 15, Prior to the year 2000, the majority of studies on vitamin D deficiency in cirrhosis focused on bone demineralization and metabolism. Over the past 2 decades, there have been advances in the understanding of the pathophysiology of vitamin D deficiency and its relation to chronic liver disease. 25 Vitamin D deficiency has important implications in chronic liver disease, including associations with the degree of fibrosis and outcomes, such as infections, hepatocellular carcinoma, and mortality. 8, 10, 37, [54] [55] [56] 
Vitamin D Metabolism
The liver plays an important role in the metabolism of vitamin D, where it is hydroxylated into 25-hydroxyvitamin D (25[OH]D), the major circulating form, which is generally tested to determine a patient's vitamin D status. 25(OH)D is transported to the kidneys where it undergoes a second hydroxylation to the active form 1,25-dihydroxyvitamin D (1, 25 [OH]D). 16 
Mechanisms for Deficiency
The etiology of vitamin D deficiency in liver disease is generally multifactorial, including decreased oral absorption (eg, cholestatic liver disease or portal hypertensive enteropathy) and decreased exposure to ultraviolet light. Patients with severe cholestasis have decreased absorption of vitamin D compared to patients with milder disease. 23 Patients with severe parenchymal disease or obstructive hepatic disease may have reduced synthesis of 25(OH)D. However, the majority of the liver must be dysfunctional before synthesis is reduced. 57 Other risk factors for vitamin D deficiency include high latitudes, seasonal variation with decreased sun exposure, obesity, medications increasing vitamin D metabolism, and chronic medical conditions, such as chronic kidney disease, leading to decreased synthesis of 1,25(OH)D. 58 Cirrhosis, non-white race, acute decompensation of cirrhosis, and triceps skin fold thickness (a measurement for estimating body fat) are associated with lower vitamin D levels. 59 
Clinical Assessment and Laboratory Testing
The symptoms of vitamin D deficiency are nonspecific and include fatigue, weakness, anxiety, depressed mood, and bone, muscle, or joint pain.The symptoms may overlap with other medical comorbidities, including cirrhosis, fibromyalgia, myopathy, or chronic fatigue. 60 Vitamin D is important for bone mineralization, and severe deficiency is associated with rickets in children and osteomalacia in adults. 16 In the general population, optimal vitamin D levels range from 30 to 50 ng/mL. Vitamin D deficiency is generally defined as serum 25(OH)D levels < 20 ng/mL. Levels of 25(OH)D < 30 ng/mL are associated with an increase in parathyroid hormone, and 25(OH)D levels between 20 to 32 ng/mL are associated with an increase in intestinal calcium transport. 61, 62 As such, a vitamin D level of 21 to 29 ng/mL is generally considered a relative deficiency. 13 There is no consensus definition regarding the optimal vitamin D level for patients with chronic liver diseases, including cirrhosis. 25 
Cellular Changes and Clinical Outcomes
Vitamin D deficiency correlates with the severity of underlying chronic liver disease and is associated with worse outcomes. 20, 50, 63, 64 In patients with cirrhosis and vitamin D deficiency, levels improve with oral vitamin D supplementation and fall without supplementation. 64 In a study of 75 cirrhotic patients in an outpatient liver clinic, vitamin D deficiency correlated with the Child-Pugh score and Model for End-Stage Liver Disease scores and was associated with hepatic decompensation and mortality. 8 In a prospective study of 65 patients with cirrhosis over a 24-month period, low vitamin D levels were associated with increased mortality. 10 In a study of 88 hospitalized patients with cirrhosis, a severe deficiency (vitamin D < 10 ng/mL) occurred in 56.8% of patients, with low levels of 25(OH)D being independently associated with bacterial infections, including bacteremia, urinary tract infections, and spontaneous bacterial peritonitis. 54 
Vitamin D Replacement in Cirrhosis
Treatment recommendations for vitamin D deficiency are listed in table 3. [65] [66] [67] [68] [69] The Endocrine Society Clinical Practice Guidelines (ESCPG) recommend screening for vitamin D deficiency in patients at high risk, including those with hepatic failure, although this term is not specifically defined. 66 The European Association for the Study of the Liver (EASL) and the AASLD recommend consideration of supplementation of vitamin D for all patients with cholestatic disease for the prevention of osteoporosis. 70, 71 In their guidelines, the two societies 66 This should be followed by maintenance therapy of 1,500 to 2,000 IU/day. Higher daily doses (6,000-10,000 IU) are recommended in patients with obesity, a history of malabsorption syndromes, and patients on medications affecting vitamin D metabolism to achieve a 25(OH)D level above 30 ng/ml, followed by maintenance therapy of 3,000 to 6,000 IU/day. 66 In patients with cholestatic liver disease, the EASL recommends 400 to 800 IU/day and the AASLD recommends 1,000 IU/day for the prevention of osteoporosis. [70] [71] [72] [73] Other than these recommendations, there are not specific guidelines for vitamin D supplementation in cirrhosis. A Cochran review, which included 15 randomized clinic trials and 1,034 participants, was performed to assess the effects of vitamin D supplementation on individuals with chronic liver diseases. They found that the evidence was uncertain regarding vitamin D supplementation and its effects on mortality or other adverse events. 72 
Vitamin D Toxicity
Vitamin D toxicity is rare, but can occur from excess supplementation as a fat soluble vitamin. Toxicity is generally caused by inadvertent or unintentional ingestion of excessively high doses. Doses greater than 50,000 IU/day can raise 25(OH)D levels to > 150 ng/mL, which is associated with hypercalcemia and hyperphosphatemia. Doses of 10,000 IU/day for up to 5 months generally do not cause toxicity. 13 Hypercalcemia is generally responsible for the majority of symptoms of vitamin D toxicity. Early symptoms include gastrointestinal disturbances, such as anorexia, diarrhea, constipation, and nausea and vomiting. Symptoms occurring within days to weeks include bone, muscle, and joint pains, headaches, and arrhythmias. Other symptoms associated with hypercalcemia include frequent urination, excessive thirst, and kidney stones. 74 
VITAMIN A DEFICIENCY IN CIRRHOSIS
Vitamin A deficiency is estimated to occur in up to two thirds of patients with cirrhosis. 11 In comparison, less than 1% of the US population are estimated at risk for vitamin A deficiency. 75 Prevalence is higher among patients with poor dietary intake and those living in endemic areas, women, alcoholics, patients with cholestatic liver diseases (eg, primary biliary cholangitis [PBC], cystic fibrosis-related liver disease, and Alagille syndrome), and advanced or decompensated cirrhosis (Child-Pugh class C). 11, 21, [76] [77] [78] [79] [80] In liver failure, elevated total bilirubin and higher body mass index are predictors of profound vitamin A deficiency. 11 Epidemiologic, clinical, and diagnostic information regarding deficiency of vitamin A are listed in table 1.
Mechanisms for Deficiency
Approximately 90% of vitamin A is stored in the liver and the remaining 10% is in adipose tissue. Specifically, 80% to 95% of retinol is stored in the small perisinusoidal cells (also known as stellate cells or Ito cells). These stores are notably depleted in patients who have alcohol abuse, advanced fibrosis, or cirrhosis. Multiple mechanisms overlap, causing vitamin A deficiency in cirrhosis:
• Fat malabsorption. Fat and fat-soluble vitamin malabsorption is common in cholestatic disorders due to insufficient or abnormal bile acids in the intestinal lumen. This mechanism is particularly important in cystic fibrosis-related liver disease, even in early stages with preserved exocrine pancreatic function.
• Conversion of carotenoids. Carotenoids and vitamin A undergo 3 main metabolic pathways in the liver: cleavage to form retinol, incorporation into and release as part of very low density lipoproteins, and storage. 65 All 3 functions are impaired with loss of hepatic parenchymal cells.
• Transportation. Retinol transport in the blood requires 2 specific proteins, retinol-binding protein and transthyretin (also known as prealbumin). 65 Both proteins are synthesized by hepatocytes. Serum levels of both proteins are remarkably decreased in liver cirrhosis. 81 In PBC, impaired vitamin A mobilization outside the liver has been well described, despite adequate vitamin A absorption and sufficient hepatic stores. 82 Among all patients with cirrhosis, the severity of portal hypertension and the degree of portosystemic shunting influence the amount of vitamin A deficiency, suggesting there are additional endothelial mechanisms that have yet to be elucidated. 68 
Clinical Assessment and Laboratory Testing
Clinical findings and adaptation tests are sufficient to diagnose vitamin A deficiency. Vitamin A deficiency correlates closely with the results of visual dark adaptation tests. 83 Deficiency has also been associated with decreased taste (bitter or salt) and olfaction (pyridine recognition), but the mechanism whereby vitamin A affects taste and smell remains unknown. 84 Vitamin replacement improves taste, olfaction, and generally normalizes dark adaptation testing. 79, 84 In nonresponders to vitamin A supplementation, adding zinc replacement leads to normalization of the visual adaptation tests. Clinical diagnosis can be supported by measurement of serum retinol levels, with low levels (< 20 μg/ dL) or a decreased ratio of retinol to retinol binding protein (molar ratio < 0.8) suggesting deficiency. 85 Fasting specimens are preferred.
Earlier studies suggested that the retinol levels 5 h after a standard dose of oral vitamin A (called relative dose response) were appropriate to diagnose vitamin A deficiency. 86 Recent data show that both random serum retinol and relative dose response levels have significant variability and do not correlate well with vitamin A hepatic levels in patients with cirrhosis. 18, 21, 87 Hepatic vitamin A stores are the ideal indicator of vitamin A status in cirrhosis, but currently there is no test available for clinical use. Serum carotene levels are typically low in patients with advanced liver disease, and decreased serum carotene is a surrogate marker for fat-soluble vitamin depletion.
Cellular Changes and Clinical Outcomes
Vitamin A deficiency promotes inflammation and can accelerate liver fibrogenesis. All-trans retinoic acid, a vitamin A active metabolite, has anti-inflammatory effects, and when deficient, exacerbates a proinflammatory pathway in the liver. 88 In alcoholic cirrhosis, vitamin A deficiency increases the expression of cytokeratin antigen in hepatocytes (with or without Mallory bodies) and cholangiocytes. Overexpression of the cytokeratin antigen correlates directly with the histologic and clinical severity of alcoholic liver disease. 89 In animal studies, vitamin A deprivation alters hepatocyte cord disposition, leading to an irregular parenchymal organization, and causes deposition of fat droplets in the cytoplasm of the hepatocytes. In addition, cytoplasmic changes in myofibroblastic-like cells at the perisinusoidal space and activation of hepatic stellate cells are seen. Once stellate cells are activated, they increase synthesis of extracellular components, specifically expression of hepatic fibronectin, laminin, and collagen type IV. These findings suggest that vitamin A deficiency promotes or accelerates hepatic fibrosis. 90 At a clinical level, vitamin A deficiency is associated with progression to cirrhosis and clinical decompensation. Increased total bilirubin, liver transaminases and prothrombin time, and presence of hepatic encephalopathy (HE) and ascites were related to lower serum retinol levels. Serum retinol values of 0.78 μmol/lor less were associated with increased liver-related death. 21 Other reports did not show a significant association between vitamin A hepatic reserves and the occurrence of ascites or HE. 18 
Vitamin A Replacement
Oral vitamin replacement is safe and more efficient than intramuscular alternatives. 91 For patients with ocular symptoms, 200,000 IU of vitamin A is given in 3 doses ( Table 1 ). The first dose is given immediately on diagnosis, the second on the following day, and the third dose at least 2 weeks later. It is unclear if patients with liver cirrhosis benefit from additional doses.
Animal studies of PBC suggest that adding vitamin A to ursodeoxycholic acid significantly reduces the bile acid pool size and improves liver histology. 93, 94 Currently, there is no convincing clinical evidence supporting combined therapy in humans. Patients with cystic fibrosisrelated liver disease often require higher doses of fat-soluble vitamin supplements compared to other patients with cystic fibrosis. 78 
Vitamin A toxicity
Vitamin A supplementation (specifically synthetic vitamin A) at ten times the recommended dietary allowance, or about 50,000 IU per day can cause hepatotoxicity, venoocclusive disease, and cirrhosis. 95 
ZINC DEFICIENCY IN CIRRHOSIS
Zinc is an important micronutrient in the human body. It is an essential element for multiple metabolic and enzymatic functions and is a critical cofactor for ammonia metabolism. [96] [97] [98] [99] [100] [101] The global prevalence of zinc deficiency ranges from 4% in countries rich in animal protein and up to 73% in countries with plant-based diets. 102, 103 Zinc metabolism primarily occurs in the liver, and up to 83% of cirrhotic patients have zinc deficiency. Epidemiologic, clinical, and diagnostic information regarding zinc deficiency are listed in table 1.
Mechanisms for Deficiency
Zinc is mostly absorbed in the small intestine. [104] [105] [106] The body stores the majority in skeletal muscle and bone with 11% being stored in the liver and skin. 107 Zinc is lost in the intestine from pancreatic secretions, in the nephrons from shedding of uroepithelial cells, and through sweat, semen, hair, and menstruation. 107, 108 Malnutrition and certain diseases, including cirrhosis, can lead to zinc deficiency.
Studies dating back to the 1950s have proposed multiple mechanisms through which patients with cirrhosis develop zinc deficiency. 109 Cirrhotic patients have decreased zinc absorption, hyperzincuria, decreased serum zinc concentrations, and decreased zinc content within the liver when compared to control groups. 109, 110 Cirrhotic patients with ascites have severe muscle wasting due the catabolic state associated with a substantial loss of zinc in the urine. 111 Diuretic therapy also plays a factor as it increases renal zinc excretion and reduces serum albumin and the binding capacity for zinc. 111 
Clinical Assessment and Laboratory Testing
Zinc deficiency has been shown to cause poor wound healing, alopecia, diarrhea, weight loss, hypogonadism in men, impaired night vision, anorexia with altered taste and smell, skin manifestations, including bullous pustular dermatitis, acrodermatitis enteropathica and necrolytic acral erythema, and psychologic impairment, such as HE. Along with clinical findings, data have suggested that zinc deficiency occurs early in the course of liver disease and can lead to fatal manifestations in cirrhosis, including HE and impaired immune function. [112] [113] [114] Typically, serum and plasma zinc levels are measured to assess the degree of zinc deficiency. However, levels are falsely reduced by a multitude of factors as only 0.1% of the total body pool is contained in the circulation. Examples inlcude acute stress such as trauma, burns, blood loss, severe ischemia, major surgery, and infections. Zinc is closely bound to albumin in the circulation, and hypoalbuminemia has been related to zinc deficiency. Serum zinc levels are also influenced by diurnal variation and fasting. 115 Response to zinc supplementation is monitored by evaluating the clinical response or improvement in zinc level. 116 
Biochemical Changes and Clinical Outcomes
As the main organ involved in maintaining zinc homeostasis, the liver alters zinc levels and is influenced by zinc deficiency. Turnover studies using zinc ++ showed that complete exchange of zinc in hepatocytes required less than 2 days. 111 Zinc is an important antioxidant involved in protection against oxidative stress. Zinc deficiency affects the power of the liver to regenerate, leading to cell and tissue damage through signaling cascades that damage enzymes and mitochondrial and ribosomal structures. 111 The oxidative stress can induce increased gut permeability with endotoxemia, infections such as spontaneous peritonitis, or release of stress hormones. 111 Zinc deficiency may contribute to impaired glucose tolerance and diabetes mellitus among patients with cirrhosis. Normalization of plasma zinc levels after longterm zinc treatment in advanced cirrhosis has been shown to improve glucose tolerance. 117 Zinc deficiency is a key factor in the pathogenesis of HE as zinc is a crucial enzyme in the urea cycle to lower ammonia levels. Case studies and randomized controlled trials have shown that zinc supplementation improved cognitive function in patients with HE. 109, 111, 116, 118 In a double-blind randomized trial by Reding, et al., 118 22 cirrhotic patients with HE were given zinc acetate 600 mg/ day or a placebo for 7 days. Serum zinc was improved to normal by day 8, and supplemented patients showed improvement of HE in comparison to placebo. 118 Another trial included 39 cirrhotic patients with HE who were given zinc supplementation with 225 mg of polprezinc in addition to standard therapy of a protein-restricted diet, branched chain amino acids, and lactulose, while 38 patients were treated with standard therapy for 6 months. Zinc supplementation significantly improved HE and health-related quality of life as measured by the SF-36 questionnaire. 119 At a clinical level, zinc deficiency is associated with progression to cirrhosis and clinical decompensation.
Zinc Replacement
The dose of zinc used to treat zinc deficiency among cirrhotics is usually 50 mg of elemental zinc (zinc sulfate 220 mg), taken with a meal to prevent nausea. Doses > 50 mg/day of elemental zinc are not recommended due to the potential risk of impaired copper absorption and immune suppression. 116 
Zinc toxicity
Zinc is relatively harmless, and toxicity only occurs after exposure to high doses. 120, 121 In humans, the LD50 of zinc, the amount of a substance expected to cause death in 50% of test subjects, is estimated to be 27g per day. 122 In comparison, the recommended daily allowance of elemental zinc is 11 mg/day zinc for men and 8 mg/day for women. Intake of toxic doses of zinc is difficult, as 225-400 mg zinc is associated with nausea and vomiting. 123 Symptoms of toxic zinc ingestion include abdominal pain and diarrhea. 121 Copper deficiency is responsible for the other toxic effects of zinc. Ingestion of large doses of zinc over a prolonged period of time is associated with copper deficiency through competitive absorption between zinc and copper within enterocytes. Signs of copper deficiency include anemia, leukopenia, neutropenia, elevated cholesterol levels, and abnormal cardiac function. 121 
CONCLUSION
In summary, we provided a review of vitamin D, vitamin A, and zinc deficiency in cirrhosis. These deficiencies are common regardless of the etiology of liver disease. They occur by multiple mechanisms and correlate with disease severity, morbidity, and survival. Testing for vitamin D, vitamin A, and zinc is feasible, and repletion is practical. Current hepatology guidelines do not provide specific recommendations regarding the treatment of such deficiencies in cirrhosis. Given the individual associations of these micronutrient deficiencies with outcomes, we suggest that physicians consider routine monitoring of these levels in patients with cirrhosis and provide supplementation when a deficiency is documented. Future research is needed into the optimal regimens and benefit of treating vitamin and mineral deficiencies in patients with cirrhosis.
ABBREVIATIONS
• AASLD: American Association for the Study of Liver Diseases.
• EASL: European Association for the Study of the Liver.
• ESCPG: Endocrine Society Clinical Practice Guidelines.
• HE: hepatic encephalopathy.
• PBC: primary biliary cholangitis.
